Form 4: Kiniksa Pharmaceuticals Executive Exercises Options and Sells Shares

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, exercised share options and sold a portion of his holdings on December 16, 2024, according to a recent SEC filing.

Summary

• Eben Tessari, the Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, engaged in transactions involving the company's Class A Ordinary Shares on December 16, 2024.
• Tessari exercised 16,017 share options at a price of $1.59 per share.
• Following the option exercise, Tessari sold 23,017 Class A Ordinary Shares at a weighted average price of $20.44 per share.
• The sales were executed in multiple trades with prices ranging from $20.09 to $20.89.
• These transactions were conducted under a pre-arranged 10b5-1 trading plan established on April 29, 2024.
• After these transactions, Tessari directly owns 95,975 Class A Ordinary Shares.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the transactions of company executives.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives of publicly traded companies to avoid accusations of insider trading.
• The reported transactions are typical for executives who receive stock options as part of their compensation packages.
• The price range of the share sales is within the normal fluctuations of the stock price.

Stakeholder Impact

• The transactions may have a minor impact on the stock price due to the sale of shares by a company executive.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Eben Tessari, share options, insider trading, SEC Form 4, Class A Ordinary Shares, 10b5-1 plan, executive compensation